ANDA 209330, held by Breckenridge. Carfilzomib.
As of Nov 16, 2026, ANDA 209330 (Carfilzomib), held by Breckenridge, was first approved by FDA on Jun 11, 2021, with 0 approved supplements and 0 published complete response letters.
| Jun 11, 2021 | Original application | Approved | |
| Jun 11, 2021 | Original application | Tentative approval | None posted |
| Carfilzomib10MG/VIAL · powder;intravenous | Carfilzomib | Discontinued |
| Carfilzomib60MG/VIAL · powder;intravenous | Carfilzomib | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters